Antiangiogenic therapy using Semliki Forest virus ( SFV ) carrying Endostatin gene for malignant brain tumor was investigated to improve the therapeutic efficacy. The efficiency of SFV -mediated gene delivery was first evaluated for B 16 cells and compared with the efficiency in cells of endothelial origin ( HMVECs ). HMVECs are more susceptible to SFV infection than B 16 cells. For the in vivo treatment model, phosphate -buffered saline, SFV -LacZ, retrovirus vector GCsap -Endostatin, and SFV -Endostatin were injected to mice bearing B 16 brain tumors. A very significant inhibition of tumor growth was observed in the group that had been treated with SFV -Endostatin. A marked reduction of intratumoral vascularization was seen in the tumor sections from the SFV -Endostatin group compared with tumor sections from the SFV -LacZ or GCsap -Endostatin groups. Moreover, at day 7 after intravenous administration of SFV -Endostatin, the serum level of endostatin was augmented more than 3 -fold compared to that after intravenous administration of GCsap -Endostatin. The results indicated that treatment with SFV -Endostatin inhibited the angiogenesis with established tumors. Gene therapy with Endostatin delivered via SFV may be a candidate for the development of new therapy for brain tumors. Cancer Gene Therapy ( 2001 ) 8, 796 -802 
T he prognosis of patients with malignant brain tumors has not improved much in recent years. Current treatments, including surgery, radiation, and chemotherapy, do not change the prognosis of malignant brain tumors. Therefore, the development of novel therapies for malignant brain tumors is essential.
Tumors are dependent on angiogenesis for growth, 1 and therefore the treatment of brain tumor patients with inhibitors of angiogenesis is an attractive novel strategy. Many of these biological agents are not stable in vitro and are difficult to produce in large quantities. 2 For these reasons, antiangiogenic gene therapy has been proposed as an alternative to treatment with recombinant protein. 3, 4 Gene therapy of cancer has traditionally attempted to target tumor cells with toxic or immunogenic transgenes. The apparent lack of toxicity of antiangiogenic agents suggests that maximizing circulating levels of these endogenous agents may be a more appropriate gene therapy strategy. 3 The goal of this therapy would be to create a situation where the host becomes an endogenous factory producing high circulating levels of the gene product. Because current gene therapy is mainly conducted using adenovirus or retrovirus vectors and has not achieved satisfactory results, we investigated the ability of SFV vector to elevate circulating endostatin levels in mice as an approach to treatment of brain tumors.
Viral vectors commonly used for therapeutic DNA delivery include replication -deficient forms of adenovirus and retroviruses. Although retroviruses have the advantage of mediating stable gene transfer with a low potential for immunogenicity, retrovirus vector delivery systems have some problems with respect to therapeutic use, including difficulties in producing high titers of retroviruses, the fact that only actively dividing cells are capable of being infected and the possibility of insertional mutagenesis. 5 The adenovirus vector system, although capable of delivering genes with high efficiency to a wide spectrum of nondividing cells in vivo, 6 unfortunately produces only transient expression of various gene products. This transient expression may result from a strong immune response of host cells against the adenovirus.
7 Semliki Forest virus ( SFV ), a member of the Alphaviruses, has received considerable attention for use as a virus -based expression vector. The SFV expression system differs from currently available viral delivery systems in that SFV is an RNA virus and is known to generate high levels of protein expression in vitro. SFV is also less pathogenic 8 to humans than some other viral delivery systems. SFV is a self -amplifying expression vector, with the advantages of ease of production of high -titered stocks of infectious particles, ability to infect nondividing cells, and high -level expression of transgenes. 9 We have reported the usefulness of SFV-mediated immunogene therapy for malignant glioma.
10,11
The studies presented here were performed to evaluate the efficacy of genetically modified SFV for producing endostatin. The strategies were studied in a model of active gene therapy for brain tumors.
MATERIALS AND METHODS

Cell lines and animal models
The B 16 cell line ( derived from a C57BL / 6 mouse ) and human microcapillary endothelial cells (HMVECs ) were kindly provided by Riken Cell Bank (Tsukuba, Japan ). Baby hamster kidney ( BHK ) cells were obtained from Invitrogen ( San Diego, CA ). The amphotropic packaging cell line PA317 and the gibbon ape leukemia virus packaging cell line PG13 were kindly provided by Dr. M. Onodera. 12 The cell lines were grown in MEM medium (Gibco -BRL, Gaithersburg, MD ) containing 10% FCS. All cell lines were shown to be free from mycoplasma contamination. All experiments used 6 -to 12-week -old female C57BL / 6 mice (The Jackson Laboratory, Bar Harbor, ME ), which were maintained in a virus -free environment and treated in accordance with the NIH Laboratory Animal Resources Commission standards.
Cloning of the murine endostatin gene
Murine cDNA was obtained by isolating RNA (Rneasy Mini Kit; Qiagen, Valencia, CA ) from C57BL /6 mouse liver and reverse transcribing it with Moloney murine leukemia virus reverse transcriptase (Life Technologies, Gaithersburg, MD ). The murine endostatin cDNA was cloned into the pSecTag 2 vector (Invitrogen, San Diego, CA ) after amplification by PCR using the following primers: sense (GATCTCTAGACCACCATGCATACT-CATCAGGACTT ) and antisense ( ACTGGAGAAA-GAGGTTTATCTAGCTACTAG ). The plasmid DNA was amplified in DH5 cells and the signal sequence (IgK Leader ) and murine endostatin sequence were confirmed ( ABI Prism 310 autosequencer; PE Applied Biosystems, Foster City, CA ).
Generation of SFV -Endostatin particles
The plasmids pSFV3 and pSFV3 -LacZ (Life Technologies ) each contain an SP6 promoter, a 7 -kb fragment encoding the SFV RNA replicase, and a subgenomic promoter that is bound by the SFV RNA replicase and directs synthesis of a large quantity of subgenomic RNA. The helper plasmid pSFV-Helper 2, which contains the genes for the structural proteins (capsid, E3, E2, 6K, and E1 ) required for packaging of the viral genome, was used for construction of the recombinant envelope gene. Retrovirus vector GCsap was kindly provided by Dr. M. Onodera. 12 The murine endostatin gene was cloned into pSFV3 from pSecTag 2 -mEndostatin. SFV-mEndostatin RNA was transcribed in vitro and capped using SP6 RNA polymerase and capping analog from Life Technologies. For cotransfections of helper and expression RNA into BHK cells, electroporation was performed. After electroporation, cells were transferred to 10 mL of MEM containing 5% FCS and incubated for 12 hours. Cells were then washed with phosphate -buffered saline ( PBS ) and incubated in 10 mL of Opti -MEM medium (Gibco -BRL ) without FCS. After 24 hours, culture supernatants containing recombinant SFV particles were harvested and aliquots were stored at À 808C. Retroviral particles were also generated as described elsewhere. 12 Briefly, after cloning mEndostatin cDNA into the GCsap vector, the amphotropic packaging cell line PA317 and the gibbon ape leukemia virus packaging cell line PG13 were used to generate the retrovirus particles. The infectivity of the recombinant viruses in BHK and B 16 cells was determined by transfer of the SFV and retroviral particles that could transduce the -galactosidase gene. Various dilutions of virus -containing culture supernatants were added to adherent cells (2Â10 5 ) in six -well plates. After a 1 -hour incubation at 378C, cells were washed with PBS and incubated in growth medium at 378C for 24 hours. Viral infection was evaluated by X -gal staining. Briefly, cells were fixed in PBS containing 0.5% glutaraldehyde for 15 minutes and then washed with PBS three times. Cells were then stained with PBS containing 1 mg / mL X -gal, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 1 mM MgSO 4 at 378C for 2 hours.
Functional assay of virally generated endostatin
The B 16 cell line was infected as above with SFVmEndostatin or SFV-LacZ at various multiplicities of infection (MOIs ). Supernatants were harvested 24 hours later and centrifuged as above. Supernatants were analyzed for their ability to inhibit endothelial cell proliferation, as described previously. 13 Briefly, 1000 human capillary endothelial cells ( HMVECs ) were plated in complete medium in each well of collagen I -coated 96 -well plates and control represents the value for the supernatant of uninfected cells.
In vivo production of endostatin
Fifteen 8 -week -old female mice were injected in the tail vein with 10 9 pfu SFV-mEndostatin or no virus in 100 L of PBS to assess the dose -response and toxicity. These mice were monitored for 14 days, euthanized, and autopsied. On days 1, 3, 7, 10, and 14, blood samples were obtained by cardiac puncture (n = 3 animals /treatment group per time point ). Plasma endostatin levels were determined by ELISA.
In vivo activity of endostatin
In a treatment experiment, mice were injected intracranially or subcutaneously with 10 5 B 16 cells in 2 L of PBS as previously described.
14 Two, 7, and 14 days later, mice received injections of 10 8 pfu SFV-mEndostatin, SFVLacZ, GCsap -mEndostatin or no virus, as described as above. Subcutaneous tumors were measured in two dimensions using calipers. Tumor volume was calculated according to the formula: volume ¼ width 2 Â length Â 0:52:
Survival of the mice was monitored for the evaluation of the intracranially transplanted group.
Statistical analysis
Survival curves and median survivals were determined using the method of Kaplan and Meier. Survival data were compared using Wilcoxon's test. Student's t test was used for calculating the significance of other data. Statistical significance was determined at the <.05 level.
RESULTS
SFV -mediated endostatin administration in murine brain tumor model
Recombinant SFV virus particles carrying a mouse endostatin gene were injected into mice that had received B 16 YAMANAKA, ZULLO, RAMSEY, ET AL: ANTIANGIOGENIC THERAPY FOR MALIGNANT BRAIN TUMOR cell transplants, while other groups of mice were inoculated with SFV-LacZ or GCsap -mEndostatin. These three groups of mice were treated every week with injections of these recombinant virus particle, and the development of tumors was compared with that in uninfected controls. All of the mice were sacrificed and complete necropsy was performed.
Antitumor effect of SFV -mEndostatin in vitro
SFV-LacZ and GCsap -mEndostatin were used as control viruses throughout this study. The efficiency of SFVmediated gene delivery was first evaluated for B 16 cells and compared with the efficiency in HMVECs. For this purpose, we analyzed the proportion of cells that had been infected with the SFV-LacZ reporter virus 48 hours after addition of the virus to the cells. As shown in Figure 1 , a dose -dependent increase of -galactosidase -positive cells was observed for both cell lines, with an ID40 ( the MOI required to infect 40% of the cell population ) of 10 and 50 infectious particles per cell (pfu /cells ) for HMVECs and B 16 cells, respectively. The conclusion that HMVECs are more susceptible to SFV infection than B 16 cells was also supported by specific anti -endostatin ELISA analysis of the cell supernatants after infection with SFV-mEndostatin.
The ability of SFV-mediated delivery of endostatin to specifically block proliferation of endothelial cells in vitro was then analyzed. The number of cells that survived infection with SFV was quantified after 4 days. In this assay, the proliferation of HMVECs was found to be sensitive, in a dose -dependent manner, to infection with SFV-mEndostatin, with an ED50 (defined as the MOI required for a 50% inhibitory effect) in the range of 400 pfu/cell. In contrast, infection of HMVECs with the control virus had only a marginal effect, even at the highest dose tested (Fig 2 ) . B 16 cells were found to be less susceptible than HMVEC -1 cells to growth inhibition by SFV-mEndostatin in this assay at all MOIs tested.
Antitumor effects of SFV -Endostatin in vivo
In a first experiment, mice were randomized 10 days after tumor grafting, when the tumors had reached a mean volume of 150 mm 3 . Treatment was initiated at this time by intratumoral injection of recombinant virus ( 5Â10 9 pfu per injection). Tumor growth was then monitored on day 30 postgrafting. As shown in Figure 3 , a very significant inhibition of tumor growth was observed in the group that had been treated with SFV-Endostatin. At completion of the experiment, SFV-Endostatin -injected tumors were much smaller than tumors solely injected with the SFVLacZ virus or GCsap -mEndostatin. Our finding that endostatin gene delivery by itself had no significant effect on tumor growth indicates the importance of the viral vector for endostatin -based antiangiogenic approaches to Figure 5 . PBS, SFV -LacZ, SFV -mEndostatin or GCsap -mEndostatin was injected into the tail vein. Serum was harvested on day 1, 3, 7, 10 or 14 and endostatin levels were determined by ELISA. The serum level of endostatin was augmentated more than 3 -fold on day 7 after intravenous administration of SFV -mEndostatin compared to the level after injection of GCsap -mEndostatin.
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When treatment was initiated at a later stage (i.e., 14 days postgrafting, when the tumor volume had reached a mean value of 180 mm 3 , SFV-Endostatin treatment caused a less significant inhibition of tumor growth as assessed 30 days postgrafting.
Treatment with SFV-LacZ had very little or no effect on the survival of mice after intracranial tumor grafting. SFVEndostatin gene delivery extended survival in this experiment, as shown in Figure 3B , although only a 35% survival rate was observed in the SFV-Endostatin -treated group.
SFV -Endostatin inhibits tumor angiogenesis
Intratumoral vascularization was assessed immunohistologically by using anti -mouse VEGF antibody (Santa Cruz Biotechnology, Santa Cruz, CA ) and quantified by assessing the area per microscopic field that scored positive in this assay ( Fig 4A ) . As shown in Figure 4B , a marked reduction of intratumoral vascularization was seen in the tumor sections from the SFV-Endostatin group as compared with tumor sections from the SFV-LacZ or GCsap -mEndostatin groups.
Serum level of endostatin was augmented after intravenous administration of SFV -Endostatin
PBS, SFV-LacZ, SFV-Endostatin, or GCsap -mEndostatin was injected into the tail vein and serum was harvested thereafter at days 1, 3, 7, 10, and 14. Endostatin levels in the serum were determined by ELISA. As shown in Figure 5 , at day 7 after intravenous administration of SFV-Endostatin, the serum level of endostatin was augmented more than 3 -fold compared to that after intravenous administration of GCsap -mEndostatin. There was no toxic effect on the mice in this experiment ( data not shown ).
DISCUSSION
Surgical removal of human tumors often leads to rapid growth of distant metastases. 15, 16 These clinical observations have been investigated in animal tumor models where growth of small lesions is suppressed in the presence of a large primary tumor, and the phenomenon is termed concomitant tumor resistance. 17, 18 O'Reilly et al 19 have proposed that a primary tumor, although capable of stimulating angiogenesis in its own vascular bed, simultaneously inhibits angiogenesis in vascular beds of secondary metastatic lesions. Soluble factors produced by the primary tumor are responsible for suppression of distant tumor growth, 19 -21 and two such factors, identified using murine models, are angiostatin 19 and endostatin. 20 Endostatin is a C -terminal fragment of collagen 18 that was first purified from conditioned medium obtained from the EOMA murine hemangioendothelioma cell line. 20 This factor inhibits the growth of endothelial cells in vitro, and systemic administration of purified recombinant endostatin has been shown to inhibit the growth of established tumors and metastases in vivo. 22 -25 Those experiments demonstrated that endostatin has intrinsic antiangiogenic activity against tumors, suggesting that angiogenesis and growth of individual lesions are dependent on the local balance of angiogenic and antiangiogenic factors. 3, 26 We have constructed a recombinant SFV expressing biologically active murine endostatin, as shown in both in vitro and in vivo models of angiogenesis. Treatment of tumor-bearing mice with SFV-mEndostatin led to a tumorsize reduction in subcutaneous and brain tumor models. Histological findings demonstrated decreased tumor vascularization in the endostatin-treated animals. Difficulties in the large-scale production of recombinant endostatin have hampered the clinical utilization of this molecule. In this report, we demonstrated that a single injection of SFVEndostatin resulted in high endostatin serum levels that were more than three times higher than those achieved with a retroviral gene delivery system. This system results in much higher endostatin levels than those reported for other delivery systems such as nonviral gene transfer methods. 13,20,27 -29 Endostatin dose and inhibition of endothelial cell proliferation have been shown to be positively correlated. 20, 30 Dhanabal et al 27 reported that low levels of endostatin did not induce endothelial cell apoptosis in vitro. Sauter et al 31 reported that the effective dose of recombinant endostatin protein for tumor growth inhibition was more than 10 -20 mg /kg per day. This dose prevented metastasis completely, whereas only partial prevention of metastasis was reported when a low-expression gene delivery system was used. 13 SFV is being developed as a vector for expression of heterologous genes and has many advantages as an expression vector system. In SFV systems, because helper RNA does not contain a packaging signal, it dose not form a defective interfering particle or become packaged together with recombinant RNA. Furthermore, replication occurs entirely in the cytoplasm of the infected cells via RNA molecules, without a DNA intermediate. 9 This is in contrast with retroviruses, which must enter the nucleus and integrate into the host genome for initiation of vector activity. Thus, retrovirus vectors have applications for long -term expression of foreign genes, whereas SFV is useful primarily for transient high level expression. Furthermore, although adenovirus vectors can express high levels of foreign genes, these systems are more complex than SFV and express many highly antigenic virus -specific gene products, including structural proteins. 32 In contrast, the current SFV vector expresses only the four viral replicase proteins (ns P 1 -4 ) required for RNA amplification in the infected cells. This self -replicating RNA was shown to produce more than 200% the amount of antigen produced using a conventional DNA immunogen. 33 This system has been found to express significant quantities of heterologous proteins in vitro 34 and in vivo. In summary, we have shown that high circulating levels of biologically active endostatin could be achieved through SFV-mediated gene therapy. In the present form, endostatin itself does not provide a cure for brain tumors; however, it may be useful in combination with other treatment modalities. Thus, the self -replicating SFV system could serve as a powerful tool for treating malignant brain tumors. 
CONCLUSIONS
A treatment protocol using SFV-endostatin showed antitumor effects in vitro and in vivo. SFV-mEndostatin -treated mice also showed decreased tumor angiogenesis. The serum level of endostatin was more than three times higher after intravenous administration of SFV-mEndostatin than after similar administration of endostatin -expressing retrovirus vector GCsap -mEndostatin. Thus, the self -replicating SFV system may provide a novel approach for the treatment of malignant brain tumors.
